TheraPeptics Overview

  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 2

TheraPeptics General Information


Owner and operator of an AI based therapy discovery and development company intended to synthesizine new amino-acid polymers, called peptidomimetics, as simplified analogues of natural antimicrobial peptides (AMPs). The company's products are nature inspired AMPs/host defense peptides from animals with superior immune systems, carried by novel drug delivery tools to the right place at the right time to cure animals and humans, enabling patients to have therapies for viruses, bacteria, special immune cell subpopulations and cancer tissues of all types.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Doylestown, PA
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

TheraPeptics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Accelerator/Incubator 01-Aug-2017 Completed Startup
1. Grant 01-Jan-2017 00000 Completed Startup
To view TheraPeptics’s complete valuation and funding history, request access »

TheraPeptics Executive Team (1)

Name Title Board Seat Contact Info
Tony Barnes Chief Executive Officer
To view TheraPeptics’s complete executive team members history, request access »

TheraPeptics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
XLerateHealth Accelerator/Incubator Minority 000 0000 000000 0
L'Agence Nationale de la Recherche Government 000 0000 000000 0
To view TheraPeptics’s complete investors history, request access »